(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST
Status:
Completed
Trial end date:
2021-09-15
Target enrollment:
Participant gender:
Summary
This is an open-label, randomized, Phase 3 study in patients with locally advanced
unresectable or metastatic GIST (advanced GIST) of avapritinib (also known as BLU-285) versus
regorafenib in patients previously treated with imatinib and 1 or 2 other TKIs.